IQVIA Holdings, Inc.
IQV
$257.30
+0.12%
IQVIA Holdings Inc. is a global leader in clinical research and technology solutions for the life science industry, formed in 2016 from the merger of Quintiles and IMS Health. It provides outsourced clinical development services and commercial solutions, leveraging extensive healthcare data and analytics to support biopharmaceutical firms, providers, payers, and policymakers. The company is currently attracting investor attention due to its strong revenue growth, margin expansion, and strategic focus on AI-driven analytics, which have driven a significant stock rally over the past year. Recent analyst actions, including upgrades from TD Cowen and Barclays, reflect growing confidence in its growth trajectory, while the broader healthcare sector's interest in data-driven solutions continues to bolster its outlook.…
IQV
IQVIA Holdings, Inc.
$257.30
Related headlines
Investment Opinion: Should I buy IQV Today?
Rating: Buy. IQVIA's strong growth, margin expansion, and strategic position in healthcare data and AI justify a positive outlook, supported by a 'Strong Buy' analyst consensus and an average target of $276.28, implying 3.2% upside. The company's accelerating revenue growth (8.41% YoY) and high ROE of 20.91% indicate a high-quality business with durable competitive advantages.
Sign up to view all
IQV 12-Month Price Forecast
IQVIA's growth trajectory, margin expansion, and strategic focus on AI-driven analytics position it well for continued outperformance. The stock's valuation is demanding but justified by its high ROE and accelerating revenue. However, the high debt load and competitive pressures warrant a medium confidence level. I would upgrade my stance if revenue growth exceeds 10% and margins expand, or downgrade if growth falls below 5% or debt-to-equity rises above 3.0x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $276.28 and implied upside of +7.4% versus the current price.
Average Target
$276.28
0 analysts
Implied Upside
+7.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$240 - $300
Analyst target range
The target price range spans from $240.00 to $300.00, with the high target suggesting a 12.0% upside, likely assuming continued strong growth and multiple expansion. The low target implies a 10.4% downside, possibly pricing in risks such as margin compression or competitive pressures. The wide spread of $60 between low and high targets indicates elevated uncertainty about the company's future performance. However, the recent upgrades and strong earnings momentum suggest that analysts are increasingly confident in IQVIA's ability to sustain its growth trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: IQV Investment Factors
IQVIA presents a compelling growth story with accelerating revenue, expanding margins, and strong analyst support, but it faces significant risks from high leverage, a rich valuation, and near-term price overextension. The bull case is currently stronger, driven by robust fundamentals and positive industry tailwinds, yet the stock's premium valuation and debt load warrant caution. The most critical tension is whether IQVIA can sustain its double-digit earnings growth to justify its premium PE, or if margin compression and rising interest costs will dampen the optimism. If growth continues as projected, the stock has room to run, but any disappointment could trigger a sharp de-rating.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 8.41% YoY to $4.151B, up from 4.5% growth in Q1 2025, indicating accelerating demand for R&D and commercial solutions. This marks the strongest quarterly growth in recent quarters, driven by increased biopharma outsourcing.
- Strong Margin Expansion Potential: Operating margin improved to 14.02% (TTM) from 12.96% in Q1 2025, and net margin rose to 8.34% from 6.50% a year ago. The forward PE of 18.52x implies the market expects continued earnings growth from operational leverage.
- High ROE and Profitability: ROE stands at 20.91%, well above the industry average, reflecting efficient capital deployment. Net income of $274M in Q1 2026 grew 10% YoY, and EPS of $1.63 beat estimates, showcasing strong bottom-line performance.
- Analyst Upgrades and Strong Consensus: Recent upgrades from TD Cowen and Barclays, along with a 'Strong Buy' consensus (mean 1.43), signal growing confidence. The average analyst target of $276.28 implies a 3.2% upside, with a high target of $300 suggesting 12% potential.
Bearish
- High Debt-to-Equity Ratio: Debt-to-equity is 2.49x, indicating significant leverage from the Quintiles-IMS merger. Interest expense of $192M in Q1 2026 consumes a large portion of operating income, increasing financial risk if rates rise or cash flow falters.
- Valuation Premium to Industry: Trailing PE of 28.50x is 29.5% above the industry average of 22x, and PEG ratio of 6.34x suggests the stock is expensive relative to its growth rate. This premium could compress if growth decelerates or market sentiment shifts.
- Low Current Ratio Indicates Liquidity Risk: Current ratio of 0.75x implies short-term liabilities exceed current assets, which could strain liquidity if not managed carefully. This is partly due to high debt levels and may limit financial flexibility.
- Stock Near 52-Week High: At $267.77, the stock trades at 98.5% of its 52-week high of $271.80, leaving limited upside in the near term. The 6-month gain of 53.46% suggests the stock may be overextended, risking a pullback.
IQV Technical Analysis
IQVIA is in a powerful uptrend, with the stock price at $267.77 as of September 4, 2026, up 45.46% over the past year. The current price sits at 98.5% of its 52-week range (low of $154.50, high of $271.80), indicating the stock is trading near its highs, which typically signals strong momentum but also potential overextension. The 6-month price change of 53.46% underscores the sustained bullish trend, with the stock consistently making higher highs and higher lows.
Beta
1.19
1.19x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$155-$272
Price range past year
Annual Return
+39.9%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | +5.5% | -1.6% |
| 3m | +41.8% | +2.2% |
| 6m | +56.2% | +14.4% |
| 1y | +39.9% | +16.2% |
| ytd | +14.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
IQVIA's revenue growth is accelerating, with the most recent quarter (Q1 2026) reporting revenue of $4.151 billion, up 8.41% year-over-year, compared to 4.5% growth in the prior year quarter. The company has consistently grown revenue over the past several quarters, from $3.829 billion in Q1 2025 to $4.151 billion in Q1 2026, reflecting robust demand for its R&D and commercial solutions. The Research and Development Solutions segment, which generated $2.397 billion in the latest quarter, is a key growth driver, benefiting from increased outsourcing by biopharma clients.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
32.6%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Given IQVIA's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 28.50x, while the forward PE is 18.52x, indicating the market expects significant earnings growth. The gap between trailing and forward PE suggests that earnings are projected to increase substantially, likely due to margin expansion and operational leverage. IQVIA's PE of 28.50x is above the industry average of 22x, representing a 29.5% premium, which may be justified by its superior growth and profitability metrics, such as a net margin of 8.34% and ROE of 20.91%.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to IQVIA's high debt-to-equity ratio of 2.49x, which amplifies interest expense ($192M in Q1 2026) and reduces net income resilience. The current ratio of 0.75x indicates potential liquidity constraints, though strong free cash flow of $2.545B TTM provides a buffer. Margin pressure is evident as gross margin declined from 33.90% in Q1 2025 to 32.64% in Q1 2026, which could squeeze profitability if not offset by operational leverage. Revenue concentration in the R&D segment (58% of Q1 revenue) exposes the company to biopharma funding cycles, which can be volatile.
FAQ
The key risks include: 1) High financial leverage with a debt-to-equity ratio of 2.49x, which increases vulnerability to interest rate hikes and economic downturns. 2) Valuation risk, as the stock trades at a 29.5% premium to the industry PE, leaving room for multiple compression. 3) Competitive risk from tech-enabled CROs like Veeva, which could erode IQVIA's market share in commercial solutions. 4) Operational risk from margin pressure, as gross margin declined from 33.90% to 32.64% YoY. The most severe risk is a combination of these factors leading to a de-rating and a potential drop to the 52-week low of $154.50, which would represent a -42.3% loss from current levels.
The 12-month forecast for IQV is moderately bullish, with a base case probability of 50% targeting a range of $260-$280, aligning with the analyst average of $276.28. The bull case (30% probability) sees the stock reaching $280-$300, driven by strong growth and margin expansion, while the bear case (20% probability) could see it fall to $220-$240 if growth disappoints. The most likely scenario is the base case, assuming IQV maintains its current growth trajectory and manages its debt effectively. Investors should monitor quarterly earnings and margin trends to gauge which scenario is unfolding.
IQV is currently overvalued relative to its industry peers, with a trailing PE of 28.50x versus the industry average of 22x, representing a 29.5% premium. However, the forward PE of 18.52x suggests the market expects significant earnings growth, which could justify the premium if achieved. The PEG ratio of 6.34x is high, indicating that the stock is expensive relative to its growth rate. Compared to its own history, the stock is trading near the upper end of its valuation range, reflecting strong investor optimism. Overall, IQV is fairly valued to slightly overvalued, and investors should wait for a pullback or a clearer margin of safety before initiating a position.
IQV is a good buy for investors with a long-term horizon who are comfortable with moderate risk. The stock has strong fundamentals, including accelerating revenue growth of 8.41% YoY and a high ROE of 20.91%, and analysts have a 'Strong Buy' consensus with an average target of $276.28, implying a 3.2% upside. However, the stock trades at a premium valuation (PE 28.50x vs. industry 22x) and has high debt, so it is not without risk. For growth-oriented investors, the potential for 12% upside to the high target of $300 makes it attractive, but those seeking value or income may find better opportunities elsewhere.
IQV is better suited for long-term investment (3-5 years) given its growth stage and strategic position in healthcare data and AI. The stock has a beta of 1.186, indicating higher volatility than the market, which may deter short-term traders. However, its strong momentum (45.46% 1-year return) could offer short-term opportunities, but the high valuation and debt levels increase the risk of a pullback. For long-term investors, the company's accelerating revenue growth and margin expansion potential provide a solid foundation for capital appreciation. A minimum holding period of 3 years is recommended to ride out market fluctuations and allow the growth thesis to play out.
